Analysts Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $5.29

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been assigned a consensus rating of “Hold” from the nine analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $5.29.

Several analysts have weighed in on RAPT shares. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $8.00 to $2.00 in a research report on Monday, November 11th. Wells Fargo & Company cut their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. HC Wainwright raised RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Thursday, December 26th. Stifel Nicolaus reissued a “hold” rating and issued a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th.

Hedge Funds Weigh In On RAPT Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Picton Mahoney Asset Management raised its holdings in RAPT Therapeutics by 994.4% in the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock worth $26,000 after acquiring an additional 14,697 shares during the last quarter. Readystate Asset Management LP purchased a new position in RAPT Therapeutics in the 3rd quarter worth approximately $36,000. Los Angeles Capital Management LLC raised its holdings in RAPT Therapeutics by 9.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock worth $348,000 after acquiring an additional 18,558 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after acquiring an additional 25,130 shares during the last quarter. Finally, Barclays PLC raised its holdings in RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares during the last quarter. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

RAPT Therapeutics Stock Performance

RAPT Therapeutics stock opened at $1.14 on Friday. The stock’s 50 day simple moving average is $1.31 and its two-hundred day simple moving average is $1.59. The stock has a market cap of $39.85 million, a price-to-earnings ratio of -0.41 and a beta of 0.03. RAPT Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $10.05.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.